Ajanta Pharma Q3 Results Review - Miss On Operating Margin: Dolat Capital
Ajanta Pharma’s revenues were slightly better than our estimates.
BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Ajanta Pharma Ltd.’s revenues were slightly better than our estimates while missed operating margin on account of forex derivative loss of Rs 369.9 million.
Ajanta’s India revenues grew by 13% YoY in Q3 driven by new launches and strong volume growth in all its focused therapies – cardiovascular, ophthalmology, dermatology and pain management, outperformed the Indian pharma market. Asia branded business grew by 17.5% YoY in Q3 FY23 seen traction in new launches while Africa branded business declined 13% YoY impacted by currency volatility.
Africa sales grew 9% YoY in constant currency terms. We expect branded generics business of India, Africa and Asia to have combined revenue compound annual growth rate of 14% over FY23E-25E, backed by medical representative productivity and new product launches.
U.S. revenue grew 60%/44% YoY/QoQ on higher Tamiflu sales benefitted from flu season which is likely to be one off opportunity.
Click on the attachment to read the full report:
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.